drugset
drugset / Trial / NCT02110420

First-in-human Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Single and Multiple Ascending Doses of CC-90001

NCT02110420 ↗

Phase 1 Completed 96 enrolled Celgene Corporation
RandomizedSingle-groupDouble-blind

Summary

First-in-human study to evaluate safety, tolerability, and pharmacokinetics of single and multiple ascending doses of CC-90001

Timeline

Start
2014-02
Primary completion
2014-09
Completion
2014-09

Drugs

EvaluationDrugModalityDoseRoute
Subject CC-90001 Small molecule 10 mg Oral
Subject CC-90001 Small molecule 30 mg Oral
Subject CC-90001 Small molecule 60 mg Oral
Subject CC-90001 Small molecule 120 mg Oral
Subject CC-90001 Small molecule 240 mg Oral
Subject CC-90001 Small molecule 480 mg Oral
Subject CC-90001 Small molecule 720 mg Oral

Indications

No indication recorded.